Concepedia

Arvind Dasari

AD

Statistics

Publications

4

Citations

92

H-Index

4

Active since

2022

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Massachusetts General Hospital

Houston Methodist

Arvind Dasari is an author at The University of Texas MD Anderson Cancer Center specializing in oncology, cetuximab therapy, and colorectal cancer.

Publications per year

2022–2025

4

Publications

4

Alliance A022104/NRG-GI010: The Janus Rectal Cancer Trial: a randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response and disease-free survival in patients with locally advanced rectal cancer

Janet Alvarez, Qian Shi, Arvind Dasari et al. · BMC Cancer · 2024 · 38 citations · Full text

, , +17

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

Van K. Morris, Christine M. Parseghian, Vahid Bahrambeigi et al. · Cancer Cell · 2025 · 22 citations · Full text

, , +17

Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable (MSS), <i>BRAF<sup>V600E</sup></i> metastatic colorectal cancer.

Van K. Morris, Christine M. Parseghian, Michelle Escano et al. · Journal of Clinical Oncology · 2022 · 17 citations

, , +17

Health-related quality of life (HRQoL) associated with fruquintinib in the global phase 3, placebo-controlled, double-blind FRESCO-2 study.

Alberto Sobrero, Arvind Dasari, Sara Lonardi et al. · Journal of Clinical Oncology · 2023 · 15 citations

, , +12

1–4 of 4